We investigated whether the striking difference in severity of coagulopathy observed between bacterial sepsis involving Neisseria meningitidis and Neisseria gonorrhoeae species is related to species-dependent abilities to directly activate coagulation. Using lipooligosaccharide (LOS)-activated gelation of Limulus amebocyte lysate, we compared the relative abilities of outer membrane LOS of 10 N. meningitidis and 10 N. gonorrhoeae strains to initiate coagulation. A wide range of procoagulant potencies was observed for each species, and there was significant overlap of potencies between species. Relative biological activities did not correlate with the oligosaccharide components as defined by LOS molecular weight or specific antigenic epitopes. Purified lipid A of two LOS strains of different potency demonstrated relative procoagulant biological activities similar to those of their parent LOSs. When these lipid A preparations were further separated by thin-layer chromatography, the most polar component of each lipid A possessed the majority of the procoagulant activity.
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We conclude that the ability of neisserial LOS to initiate coagulation ofLimulus lysate is a property of the lipid A portion of the molecule and is most likely determined by fine structural differences in the lipid A which are independent of species.
Neisserial organisms are major human pathogens, and much of the pathogenicity of both gonococcal (GC) and meningococcal (MGC) strains is attributable to their surface lipooligosaccharides (LOS) that structurally resemble and antigenically mimic human cell surface glycoproteins (20) (21) (22) . GC LOS has been demonstrated to result in toxic effects on fallopian tube epithelium (5) , possibly because of the lipid A portion of LOS (11) , and antibody to LOS contributes significantly to effective serum bactericidal activity against both species (12, 13, 32, 39) . MGC LOS have been implicated as neurovirulence factors (29) , and positive correlations have been demonstrated between LOS liberation from cultured organisms and both invasiveness of nasopharyngeal organisms and severity of disseminated disease (1) . MGC purpura also has been associated with LOS potency (6) , and initiation of coagulation is commonly observed in the setting of endotoxemia in the absence of detectable bacteremia. MGC septicemia and endotoxemia are typically associated with a marked increase in concentration of several serum lymphokines (tumor necrosis factor alpha, interleukin-1, and interleukin-6) (40), and MGC LOS can trigger the rapid release of these lymphokines in in vivo experimental animal models (41) . Since endotoxins play an important role in diseases caused by both neisseriae, it is curious that MGC septicemia commonly results in a fulminant endotoxemic syndrome of cardiovascular shock, disseminated intravascular coagulation, and multiple organ failure (3), whereas GC septicemia rarely is associated with shock. Additionally, organ involvement in disseminated GC disease, with the exception of arthritis, is typically of little clinical consequence.
Enteric endotoxins are known to vary widely in their procoagulant potencies (16, 42 LOS were suspended in endotoxin-free water by vortexing for 2 min, and serial 10-fold dilutions were prepared. A 7-log range of LOS concentrations (10 fg/ml to 100 ng/ml) was assayed for each sample. A total of 50 ,ul of LOS was added to 50 RI of LAL, and the mixture then was incubated for 4 h at 37°C (19) , with visual inspections at 15-min intervals (first hour) and then at 30-min intervals. Samples were graded for flocculation, increased viscosity, and gelation, as previously described (18) . For determination of relative potency of LOS, the least reactive LOS was defined as having a potency of 1. All other LOS were graded by comparison of their rates of gelation (at each of the concentrations prepared above) to the gelation rates of the reference (least reactive) LOS. Thus, if the gelation rate of a given LOS at a concentration of 10 fg/ml was identical to that of the reference LOS at 100 fg/ml, the given LOS demonstrated a relative potency of 10. Purified lipid A from two neisserial strains (MGC 6275 and GC 15253) was assayed for relative potency by comparison of the minimum time and concentration required to produce a gel.
Chromogenic LAL test. Lipid A components of MGC 6275, GC 15253, and GC F62 were obtained after TLC (described above), suspended in 1 ml of water with vigorous vortexing for 2 min, and then assayed for relative potency by using the chromogenic LAL test. Each lipid A component (0.05 ml) was incubated with 0.05 ml of LAL in borosilicate tubes (10 by 75 mm; VWR Scientific, San Francisco, Calif.) for 30 min in a 37°C water bath. Chromogenic substrate S-2423 (0.2 ml; Kabi Vitrum, Molndahl, Sweden) (0.25 mM stock solution in 20 mM sodium phosphate buffer, pH 7.6) was then added to each assay tube, mixed well by vortexing, and incubated for an additional 10 min at 37°C. Reactions were stopped by addition of 0.15 ml of 50% acetic acid, and A405 was measured in a Gilford model 2400-2 spectrophotometer (Gilford Instrument Laboratories Inc., Oberlin, Ohio). A standard curve was generated from a 6-log range of concentrations by using whole GC 15253 lipid A. Relative glycolipid concentrations were calculated for each extracted lipid A Fig. 1 ) for relative potency was based upon the rate of progression of each sample through pregelation changes (flocculation and increased viscosity), as previously described (18 
RESULTS
Procoagulant potencies of LOS. A total of 10 LOS from MGC isolates and 10 LOS from GC isolates were tested for LAL potency. These LOS possessed carbohydrate chains of greatly differing structure, as shown by molecular weight analysis and their abilities to bind several monoclonal antibodies to the oligosaccharide moieties. Of 20 LOS, 19 produced a solid gel at a minimum concentration of 1 ng/ml, with rates of gelation varying from <30 min to >3 h ( Table  1 ). The least potent LOS (M978) required 100 ng/ml to produce a solid gel and was thus designated the reference LOS and assigned a potency of 1. Six different potency groups were defined according to gelation time and minimum LOS concentration that produced a gel. When the remaining 19 LOS were compared for rate of gelation at multiple concentrations (over a 7-log range of concentration), their relative potencies varied from 2 to 500 times that of the reference LOS, M978 (Fig. 1) . Both MGC and GC LOSs covered the full range of potencies (Fig. 1) . Although the group of MGC species contained many more potent LOS than the GC isolates, the distributions of potencies between Procoagulant potencies of lipid A. Since the differences we observed in LAL test potency could not be attributed to the oligosaccharide moieties, we compared the Limulus reactivities of purified lipid A prepared from an LOS of low potency (GC 15253) and lipid A from an LOS of high potency (MGC 6275). GC 15253 is an isolate from a disseminated GC infection, and MGC 6275 is an isolate from an epidemic disseminated MGC infection. GC 15253 lipid A required 300 ng/ml to produce a gel, whereas MGC 6275 lipid A produced a gel at a minimum concentration of 3 ng/ml. Although both lipid A preparations demonstrated less potency than their intact LOS molecules, the relative potencies of these two lipid A preparations matched the relative potencies of their respective LOS. We compared these lipid A's by TLC in an attempt to identify a candidate lipid A component that could potentially account for the observed potency difference. Three major components were seen in both lipid A preparations, while minor GC 15253 components with R1s of 0.27 and 0.38 which were not present in MGC 6275 were observed (Fig. 2) . All of the TLC spots were examined for ability to activate coagulation with the chromogenic LAL test. Total recovered biological activity (as determined both by the sum of individual spot activities and by the activity of a mixture of all the extracted spots) was approximately 25% of that applied. For both species, half or more of the biological activity was observed in the most polar of the major lipid A components (each demonstrated an Rf of 0.20) (Fig. 2) . These lipid A components with the majority of biological activity contained phosphoryl groups, whereas phosphate was not detected in the more hydrophobic components. In a comparison of the estimated quantity of glycolipid in each of the polar (Rf = 0.20) spots of Fig. 2 with their biological activities, the relative procoagulant potencies of the two components were similar (the polar component of MGC 6275 had 1.4-fold the potency of GC 15253 on a weight basis). In contrast, the most nonpolar components (Rf = 0.45) of the two species had vastly different potencies. that were absent in MGC 6275 did not demonstrate any appreciable biological activity.
Structural compositional data have been reported for the lipid A components of GC F62 (36); therefore, we also examined these components for procoagulant biological activity. TLC analysis showed four major components, which is similar to the pattern seen with GC 15253. Also similar to the data obtained with GC 15253 was the fact that the majority of the biological activity (90% of the recovered activity in the chromogenic LAL test) resided in the polar lipid A component (data not shown). This component has been shown previously (36) to migrate on TLC as diphosphoryl lipid A.
DISCUSSION
Bacterial endotoxin is capable of initiating both the extrinsic pathway of blood coagulation, via cellular mechanisms (e.g., induction of macrophage tissue factor) (15) , and the intrinsic pathway, via direct activation of factor XII (26) . The clinical observation that coagulopathy is frequent, and often severe, in MGC disease yet absent or subclinical in GC disease might reflect a species-specific difference in procoagulant potency of the neisserial endotoxins. Therefore, our study was developed to examine whether LOS from MGC and GC species differ in their abilities to directly activate coagulation. We used activation of the sensitive model system LAL to measure direct procoagulant potency of LOS. Activation of LAL is a good marker for MGC septicemia and purpura fulminans (40) . Our findings demonstrated that neisserial LOS exhibit a wide range (500-fold) of procoagulant potencies. LAL activation was not species specific. Furthermore, when MGC and GC isolates were selected such that they had similar oligosaccharide chain lengths and antigenic structures, their relative potencies varied. Our Endotoxins generally have poor aqueous solubility, and it is possible that nonpolar components of high potency have limited ability to interact with the Limulus coagulation cascade without the presence of the more polar components to improve their bioavailability.
Compositional data for neisserial LOS (23, 24, 32, 36) have demonstrated considerable differences among strains for phosphoryl content and fatty acid heterogeneity. Detailed structural information on neisserial lipid A's (9, 36) is limited, however, and structure/function studies have not been reported. In contrast, there is a substantial literature on structure/function relationships of native lipid A from enteric (E. coli and Salmonella species) organisms as well as for well-defined synthetic lipid A's. For enteric endotoxininduced LAL coagulation, evidence exists that both the disaccharide backbone of lipid A and the monosaccharide backbones of lipid A precursors lipid X and lipid Y can activate LAL (28, 37, 38) . Maximal LAL activation requires both ester-linked fatty acids (35, 37) and branched acyloxyacyl fatty acids (9, 35) . Finally, LAL activation by enteric LPS also requires at least one phosphoryl group (28, 35, 37, 38) ; the phosphoryl group has similarly been proposed to be critical for the direct activation of factor XII (Hageman factor) by LPS (26) . This requirement for the phosphoryl group is consistent with our finding that phosphorylated, polar components of lipid A demonstrated the greatest relative biological potency in the activation of LAL. Interestingly, structural requirements of enteric glycolipids for other biological activities (e.g., pyrogenicity, complement activation, and chicken embryo lethality) (35, 37) are not necessarily the same as those for LAL activation.
Thus, the importance of both fatty acyl and phosphoryl groups of lipid A support the concept that lipid A procoagulant activity in vitro is related to the amphipathic nature of and in particular the highly ordered hydrophobic fatty acyl region, has been implicated for critical activities of LPS within the bacterial membrane (e.g., permeability barrier, cell shape, membrane fluidity, and expression of protein receptor activity) (30) . In vivo, fine structural differences between LOS may affect LOS biological reactivity or may affect other variables such as their bioavailability or rates and mechanisms of LOS clearance. Differences in shedding of LOS from organisms in vivo, similar to differences in vitro of neisserial endotoxin liberation (4), may also be a factor in the differential pathogenicity of the neisserial species. LOS bioreactivity and bioavailability, as well as different bacterial growth rates, may all contribute to the major clinical differences in severity of coagulopathy observed between GC and MGC endotoxemias.
